• Je něco špatně v tomto záznamu ?

The significance of portal vein embolization in the treatment of colorectal liver metastases

P. Zboril, K. Vyslouzil, I. Klementa, P. Skalicky, K. Vomackova, M. Cerna, K. Cwiertka,

. 2012 ; 59 (2) : 175-82.

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc12034789

The first aim of the present paper was to evaluate hypertrophy of liver parenchyma after portal vein embolization in patients after systemic chemotherapy for colorectal carcinoma metastases and planned extensive liver resections. The second aim was to study whether hypertrophy of the liver parenchyma remnant after could influence the postoperative course large liver resections in long-term chemotherapy within complex therapy of colorectal carcinoma.The prospective study comprised of 43 patients with colorectal hepatic metastases in whom liver resections of 4-5 segments were planned (Table 1). All patients underwent complex therapy of colorectal carcinoma, including chemotherapy consisting of 6-12 therapeutic cycles. Time interval between chemotherapy and liver resection was 2-24 months (mean interval of 8 months). Twenty patients whose presumed liver parenchyma remnant was less than 40% of total liver volume were indicated for portal vein embolization (mean liver parenchyma remnant of 29%). This was always embolization of the right portal branch. Twenty-three patients were primarily indicated to liver resection. RESULTS: Hypertrophy of the left liver lobe occurred in all 20 patients. After portal vein embolization, the volume of left liver increased on average from 476 ml (282-754) to 584 ml (380-892) (P < 0.05). Mean hypertrophy of left liver lobe after portal vein embolization was 28.5%. The measured parenchyma remnant after tumor resection increased from 29% up to 38% by hypertrophy. Mean values of ALT and AST in the postoperative period were significantly different in the groups in this study. The values of alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (GMT) were lower in patients after portal vein embolization (P < 0.05). Significant differences were in postoperative level of serum bilirubin, bilirubin levels in patients after portal vein embolization were 2-3 times lower than in the group of patients after immediate surgery (P < 0.05). he values of prothrombin time were also significantly lower in patients who underwent surgery without previous portal vein embolization (P < 0.05).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034789
003      
CZ-PrNML
005      
20121210094958.0
007      
ta
008      
121023s2012 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2012_023 $2 doi
035    __
$a (PubMed)22248275
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Zboril, P $u First Department of Surgery, Faculty of Medicine and Dentistry, Palacky University Olomouc.
245    14
$a The significance of portal vein embolization in the treatment of colorectal liver metastases / $c P. Zboril, K. Vyslouzil, I. Klementa, P. Skalicky, K. Vomackova, M. Cerna, K. Cwiertka,
520    9_
$a The first aim of the present paper was to evaluate hypertrophy of liver parenchyma after portal vein embolization in patients after systemic chemotherapy for colorectal carcinoma metastases and planned extensive liver resections. The second aim was to study whether hypertrophy of the liver parenchyma remnant after could influence the postoperative course large liver resections in long-term chemotherapy within complex therapy of colorectal carcinoma.The prospective study comprised of 43 patients with colorectal hepatic metastases in whom liver resections of 4-5 segments were planned (Table 1). All patients underwent complex therapy of colorectal carcinoma, including chemotherapy consisting of 6-12 therapeutic cycles. Time interval between chemotherapy and liver resection was 2-24 months (mean interval of 8 months). Twenty patients whose presumed liver parenchyma remnant was less than 40% of total liver volume were indicated for portal vein embolization (mean liver parenchyma remnant of 29%). This was always embolization of the right portal branch. Twenty-three patients were primarily indicated to liver resection. RESULTS: Hypertrophy of the left liver lobe occurred in all 20 patients. After portal vein embolization, the volume of left liver increased on average from 476 ml (282-754) to 584 ml (380-892) (P < 0.05). Mean hypertrophy of left liver lobe after portal vein embolization was 28.5%. The measured parenchyma remnant after tumor resection increased from 29% up to 38% by hypertrophy. Mean values of ALT and AST in the postoperative period were significantly different in the groups in this study. The values of alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (GMT) were lower in patients after portal vein embolization (P < 0.05). Significant differences were in postoperative level of serum bilirubin, bilirubin levels in patients after portal vein embolization were 2-3 times lower than in the group of patients after immediate surgery (P < 0.05). he values of prothrombin time were also significantly lower in patients who underwent surgery without previous portal vein embolization (P < 0.05).
650    _2
$a alanintransaminasa $x krev $7 D000410
650    _2
$a bilirubin $x metabolismus $7 D001663
650    _2
$a kolorektální nádory $x komplikace $x patologie $x terapie $7 D015179
650    _2
$a terapeutická embolizace $7 D004621
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hypertrofie $x etiologie $x terapie $7 D006984
650    _2
$a nádory jater $x komplikace $x sekundární $x terapie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a vena portae $x patologie $x chirurgie $7 D011169
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vyslouzil, K
700    1_
$a Klementa, I
700    1_
$a Skalicky, P
700    1_
$a Vomackova, K
700    1_
$a Cerna, M
700    1_
$a Cwiertka, K
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 59, č. 2 (2012), s. 175-82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22248275 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a
990    __
$a 20121023 $b ABA008
991    __
$a 20121210095034 $b ABA008
999    __
$a ok $b bmc $g 956799 $s 792286
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 59 $c 2 $d 175-82 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20121023

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...